Jio Launches Affordable Smartphone JioPhone Next, To Be Available From September
Reliance Industries Chairman and Managing director Mukesh Ambani while addressing the company's 44th Annual General Meeting virtually announced the launch of an ultra-affordable smartphone JioPhone Next which the company has jointly developed with Google.
JioPhone Next is based on an optimized OS that is leveraged from Android and Play Store with features that are built specially for JioPhone Next, Reliance Jio said in a press release.
"Google and Jio teams have jointly developed a truly breakthrough smartphone that we are calling JioPhone Next. JioPhone Next is powered by an extremely optimized version of the Android operating system. While being ultra-affordable, JioPhone Next is packed with cutting-edge features like the Google Assistant, automatic read-aloud of screen text, language translation, smart camera with augmented reality filters and much more", Mr Ambani said at the company's vurtual mega event.
JioPhone Next will be available in the market from Ganesh Chaturthi, September 10, 2020, Mr Ambani added. However the company did not announce the price details of the JioPhone Next. The phone comes with high quality camera, Google Assistant and has features which wherein the users can easily access content in choice of their local Indian language.
"Our vision is to bring affordable access to information for Indians in their own language, to build new products and services for India's unique needs, and to empower businesses with technology. I'm excited that today, we can announce the next steps in this vision, starting with a new, affordable Jio smartphone, created with Google, Sundar Pichai, " CEO, Google and Alphabet said at the launch of JioPhone Next.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.